Silo Pharma Seeks Patent for Ibogaine TBI Therapy in $6B Market
Silo Pharma filed a provisional USPTO patent for ibogaine-based compositions and methods targeting traumatic brain injury and related neuropsychiatric conditions. The global TBI therapeutics market is projected to reach $6.0 billion by 2032, and early data show ibogaine protocols may increase cortical thickness and reduce depression and anxiety.
1. Provisional Patent Filing
Silo Pharma filed a provisional patent titled “Compositions and Methods for Treating Traumatic Brain Injuries and/or Disorders Associated therewith with Ibogaine,” covering the use of ibogaine and related compounds to address TBI, PTSD and associated neuropsychiatric conditions.
2. Clinical and Neuroimaging Findings
Early clinical and neuroimaging results report that a single ibogaine treatment led to measurable structural brain improvements, including increased cortical thickness, subcortical volume expansion and reductions in predicted brain age, alongside significant decreases in depression and anxiety symptoms.
3. Market Opportunity and Development Strategy
The global TBI therapeutics market is estimated to reach $6.0 billion by 2032 with a 6% CAGR; Silo plans to explore differentiated ibogaine protocols and combination approaches aimed at promoting neuroplasticity, improving functional outcomes and addressing the underlying pathophysiology of TBI.